

The major myosin phosphatase in skeletal muscle is a complex between the β -isoform of protein phosphatase 1 and the MYPT2 gene product

Greg Moorhead, Deborah Johnson, Nick Morrice, Philip Cohen*

MRC Protein Phosphorylation Unit, Department of Biochemistry, University of Dundee, Dow Street, Dundee DD1 5EH, UK

Received 28 September 1998

Abstract Myosin is dephosphorylated by distinct forms of protein phosphatase 1 (PP1) in smooth muscle and skeletal muscle that are composed of PP1 complexed to different regulatory subunits. The smooth muscle myosin phosphatase (smPP1M) has been characterised previously and is composed of PP1 β complexed to M₁₁₀ and M₂₁ subunits that enhance the dephosphorylation of smooth muscle myosin, but not skeletal muscle myosin. In contrast, the regulatory subunit(s) of skeletal muscle myosin phosphatase (skPP1M) greatly enhance(s) the dephosphorylation of skeletal muscle myosin. Here we identify a regulatory subunit of skPP1M as the product of the MYPT2 gene, a protein whose sequence is 61% identical to the M₁₁₀ subunit of smPP1M. Surprisingly, the M₂₁ subunit of smPP1M appears to be produced from the same gene that encodes MYPT2.

© 1998 Federation of European Biochemical Societies.

Key words: Protein phosphatase 1; Myosin; Muscle contraction

1. Introduction

Protein phosphatase 1 (PP1), one of the major protein serine/threonine phosphatases of eukaryotic cells, participates in the control of a variety of cellular functions that include glycogen metabolism, muscle contraction, protein synthesis and pre-mRNA splicing (reviewed in [1–3]). It is now established that each of these physiological processes is regulated by a distinct form of PP1 in which the phosphatase catalytic subunit is complexed to specific targeting subunits containing an Arg/Lys-Val/Ile-Xaa-Phe/Trp motif that binds to a hydrophobic groove on the surface of PP1 [2,4,5]. These proteins not only direct PP1 to particular subcellular locations, but also modify its specificity in unique ways and confer the ability to be regulated by extracellular signals.

A form of PP1 that is associated with myofibrils [6] and has enhanced myosin phosphatase activity compared to the free catalytic subunit [7] was identified in skeletal muscle many years ago and termed PP1M. An enzyme with these properties was highly purified from the myofibrillar fraction of skeletal muscle and shown to be a complex between the catalytic subunit of PP1 and another protein(s) that greatly enhanced the rate of dephosphorylation of skeletal muscle myosin [8]. Subsequently, two such forms of skeletal muscle PP1M were resolved by chromatography on MonoQ termed PP1M α and PP1M β . Both enzymes were heterodimers in which the PP1 catalytic subunit was complexed to proteins with apparent molecular masses of 33 kDa (M α) and 50 kDa (M β) [9].

A form of PP1M was purified to homogeneity from chicken gizzard smooth muscle and shown to be composed of the β -isoform of PP1 bound to an 'M complex' consisting of two other proteins with apparent molecular masses of 130 kDa and 20 kDa [10]. Subsequent cDNA cloning revealed that the true molecular masses of the latter proteins were 110 kDa [11] and 21 kDa [12] and they were therefore termed the M₁₁₀ and M₂₁ subunits. cDNAs encoding proteins that are highly homologous to the M₁₁₀ subunit from avian gizzard were also cloned from mammalian libraries [12–14]. The M₁₁₀ subunit from chicken gizzard is not only complexed to the M₂₁ subunit, but also to PP1 [10] and the Arg-Val-Lys-Phe sequence near its N-terminus appears to be critical for interaction with the phosphatase catalytic subunit [15]. In contrast the binding site for the M₂₁ subunit is near the C-terminus of the M₁₁₀ subunit [15]. Both the M₁₁₀ and M₂₁ subunits are myosin-binding proteins [16].

The binding of the chicken gizzard M₁₁₀ subunit to PP1 was found to cause a several-fold enhancement of the rate of dephosphorylation of smooth muscle myosin, but did not increase the rate of dephosphorylation of skeletal muscle myosin [10]. In contrast, the equivalent proteins in skeletal muscle enormously enhanced (25-fold) the rate at which PP1 dephosphorylated skeletal muscle myosin, with a more modest (4-fold) effect on the dephosphorylation of smooth muscle myosin [9,10]. These observations indicated that M α and M β from skeletal muscle were distinct gene products from their counterparts in smooth muscle.

Recently, a cDNA was cloned from a human brain library encoding MYPT2 (myosin phosphatase targeting subunit 2), a 110 kDa protein whose sequence is 61% identical to that of the M₁₁₀ subunit from smooth muscle [17]. However, the mRNA encoding MYPT2 was most abundant in cardiac muscle and skeletal muscle [17]. Here we show by peptide sequencing that the 33 kDa M α and 50 kDa M β subunits of skeletal muscle PP1M α and PP1M β correspond to N-terminal fragments of MYPT2, indicating that MYPT2 encodes the myosin-targeting subunit of skeletal muscle PP1M.

The C-terminal 72 residues of the M₁₁₀ subunit from chicken gizzard are 43% identical to residues 87–161 of the M₂₁ subunit [12]. However, a second form of the M₁₁₀ subunit from avian or mammalian smooth muscle can be produced by alternative splicing, whose C-terminal sequence is extremely similar (but not identical) to the C-terminal 50 residues of the M₂₁ subunit from chicken gizzard [12]. These observations led us to speculate that the M₂₁ subunit from chicken gizzard might be transcribed from a second M₁₁₀ gene [12]. This hypothesis appears to be correct because the amino acid sequence of the M₂₁ subunit from chicken gizzard is virtually identical to the C-terminus of the protein encoded by the human MYPT2 gene.

*Corresponding author. Fax: (44) (1382) 223778.

2. Materials and methods

2.1. Isolation of tryptic peptides from rabbit skeletal muscle PP1M

PP1M α and PP1M β were purified to homogeneity from the myofibrillar fraction of rabbit skeletal muscle by affinity chromatography on microcystin-Sepharose and chromatography on MonoQ [9]. The preparations were subjected to SDS-polyacrylamide gel electrophoresis and the bands corresponding to PP1, M α and M β , excised and digested with trypsin [18]. The resulting peptides were chromatographed on a C18 column and analysed on an Applied Biosystems 476A Amino Acid Sequencer [18].

2.2. Preparation of tissue extracts

Tissues were rapidly removed post mortem, frozen in liquid nitrogen, ground in a pestle and mortar and homogenised with 6 vols of 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% (by vol) 2-mercaptoethanol, 0.2 mM phenylmethylsulphonyl fluoride, 1 mM benzamide and 10 μ g/ml of the proteinase inhibitors leupeptin, chymostatin, pepstatin and lima bean trypsin inhibitor. The homogenates were then centrifuged at 13 000 \times g for 5 min at 4°C, the supernatants removed and denatured in SDS by heating for 5 min at 95°C.

2.3. Antibodies and immunoblotting

Polyclonal antibodies were raised in sheep against the PP1M holoenzyme from chicken gizzard. Affinity-purified antibodies that recognise the M₁₁₀ subunit (but not the M₂₁ subunit) were obtained by passing the antiserum through Sepharose to which the C-terminal 290 residues of the chicken gizzard M₁₁₀ subunit had been coupled [15]. Antibodies that recognise the M₂₁ (but not the M₁₁₀ subunit) of chicken gizzard PP1M were obtained in an identical manner, except that the antiserum was passed through a Sepharose column to which the chicken gizzard M₂₁ subunit had been coupled covalently [15]. The specificity of both antibodies has been demonstrated previously [15].

3. Results and discussion

Previous peptide sequencing studies indicated that the major isoform of the PP1 catalytic subunit associated with the 'M subunit' from skeletal muscle was the β -isoform [8] (also termed PP1 δ [19]) and this finding was confirmed in the present work by sequencing additional peptides. Sequence analysis of the catalytic subunit of PP1 that is complexed to M α and M β revealed six tryptic peptides whose sequences were common to all three human isoforms of PP1, PP1 α , PP1 β and PP1 γ , and two that were specific to PP1 β (Fig. 1). Since each peptide was recovered from the tryptic digest in similar amounts, these results indicate that PP1 β is the major PP1 isoform that is complexed to M α and M β in skeletal muscle; i.e. the same isoform that is complexed to the glycogen-targeting (G_M) subunit of PP1 in skeletal muscle [20] and to the M₁₁₀ subunit in chicken gizzard [10]).

A number of tryptic peptides were also isolated after tryptic digestion of M α and M β from rabbit skeletal muscle and their sequences are shown in Fig. 1. All were virtually identical to particular regions of the protein encoded by the human MYPT2 gene [17] with 94 identities out of 100 residues sequenced. The peptide sequences were much less similar to MYPT1 (65% identity), the human homologue of the smooth muscle M₁₁₀ subunit [12,14]. Since the predicted molecular mass of MYPT2 is 110 kDa, these results indicate that M α and M β are both derived from MYPT2 by limited proteolysis during extraction and/or purification from skeletal muscle. All the peptides sequenced are located within the residues 81–412 of MYPT2, indicating that M α and M β are N-terminal fragments of this protein. Since the complexes formed between M α and PP1 or M β and PP1 both have greatly enhanced

Peptide Sequences from the M-subunits of Rabbit Skeletal Muscle PP1M	Found in	Residue number in Human MYPT2
1. GADINTVNV DGLTALHQACI	M α , M β	81-100
2. FLVENR	M β	109-114
3. ANVLQQDNEGXXPLHAAAS	M β	115-133
4. EACSI LAEALCDMDIR	M α , M β	264-279
5. LGQTPFDVADEGLVE	M β	282-296
6. LQSGLFK	M β	327-333
7. FSIMEQIPAXAQN AFR	M β	397-412
Peptide Sequences from Rabbit Skeletal Muscle PP1	Found in	Residue number in PP1 β
1. EIFLSQ	PP1M β	43-48
2. IYGFYDECK	PP1M β	132-140
3. TFTDCFNCLPIAAIVD	PP1M β	150-165
4. IMRPTDVPDTGLLCDLL	PP1M β	188-204
5. AHQVVEDGYE	PP1M β	246-255
6. YPENFFLLR	PP1M α	113-121
7. IFCCHGGLSPDLQSMEQIR	PP1M α	168-186
8. SAPNYCGEFDNAGGMMSVDE	PP1M α	267-286

Fig. 1. Amino acid sequences of tryptic peptides from PP1M α and PP1M β . The catalytic and regulatory subunits of rabbit skeletal muscle PP1M α and PP1M β were resolved by SDS-polyacrylamide gel electrophoresis, digested with trypsin and the peptides separated and sequenced as in Section 2. The positions of these peptides in the sequence of the human MYPT2 are indicated. Underlined residues are unique to the β -isoform of PP1. An X indicates residues that could not be identified unambiguously.

activity towards skeletal muscle myosin compared to the free PP1 catalytic subunit, the information required to interact with PP1 and enhance its myosin phosphatase activity are both contained in the N-terminal portion of MYPT2. This finding is as anticipated, since the first 309 residues of M₁₁₀ subunit from smooth muscle interact with PP1 and enhance the dephosphorylation of smooth muscle myosin in a similar manner to the full length protein [15]. The first 300 residues of the skeletal muscle and smooth muscle proteins both contain seven ankyrin repeats, the first of which is preceded by a canonical PP1-binding motif (see Section 1). In MYPT2, this Arg-Val-Arg-Phe sequence is located between residues 53 and 56 [17]. It will clearly be of great interest to understand why the N-terminal domain of the M₁₁₀ subunit from smooth muscle stimulates the dephosphorylation of smooth muscle myosin, but not skeletal muscle myosin, and why MYPT2 enhances the dephosphorylation of skeletal muscle myosin far more than it enhances the dephosphorylation of smooth muscle myosin.

The C-terminus of the M₁₁₀ subunit from smooth muscle is homologous, but not identical, to the M₂₁ subunit from smooth muscle (Fig. 2). Remarkably, however, the last 120 residues of chicken gizzard M₂₁ (residues 67–186) show 91% identity and nearly 100% similarity (if highly conservative replacements are included) to the last 120 residues of human MYPT2 (Fig. 2). This suggests that the M₂₁ subunit from

M21	31	K T L R H E R L S R L E . A A T T P A T S D S Y S D R A S S R S S A Y S R R E N R L A A L S S R A E
MYPT2	827	K E T W H E R L S R L E S C G S N P T T S D S Y G D R A S A R A R R . E A R E A R L A T L H S R V E
MYPT1	880	K E T Q T D S I S R Y E T S S T S A . G D R Y . D S L L G R S G S Y S L E E R . K P Y S S R L E
M110	826	R D T Q T D S V S R Y D S S S T S S . S D R Y . D S L L G R S A S Y S L E E R . K P Y G S R L E
M21	80	E E S N R D Y K K L Y E S A L S E N Q K L K S K L O E A Q L E L A D I K S K L E K A A Q Q K H E K T
MYPT2	876	E D S N R D Y K K L Y E S A L T E N Q K L K T K L O E A Q L E L A D I K S K L E K V A Q Q K Q E K T
MYPT1	926	K D D S T D F K K L Y E Q I L A E N E K L K A Q L H D T N M E L T D L K L Q L E K . A T Q R Q E R F
M110	872	K D D S T D F K K L Y E Q I L A E N E K L K A Q L H D T N M E L T D L K L Q L E K . A T Q R Q E R F
M21	130	S D R S S M L E M E K R E K R A L E R K L S E M E E E M K I L T E L K S D N Q R L K D E N G A L I R
MYPT2	926	S D R S S V L E M E K R E R R A L E R K M S E M E E E M K V L T E L K S D N Q R L K D E N G A L I R
MYPT1	975	A D R . S L L E M E K R E R R A L E R R I S E M E E E L K M L P D L K A D N Q R L K D E N G A L I R
M110	921	A D R . S L L E M E K R E R R A L E R R I S E M E E E L K M L P D L K A D N Q R L K D E N G A L I R
M21	180	V I S K L S K
MYPT2	1076	V I S K L S K
MYPT1	1024	V I S K L S K
M110	970	V I S K L S K

Fig. 2. Alignment of the M₂₁ subunit from turkey gizzard with the C-termini of human MYPT2, human MYPT1 and the rat aorta M₁₁₀ subunit. Identities with the M₂₁ subunit are highlighted in black and the most conservative replacements are shaded grey. The sequences are taken from [11,12,14,17].

chicken gizzard is likely to be produced from the gene encoding an avian homologue of MYPT2. Similarity with MYPT2 disappears N-terminal to residue 30 of the M₂₁ subunit (Fig. 2), suggesting that the N-terminal 30 residues may be encoded within an intron of the MYPT2 gene. If the M₂₁ subunit is indeed produced from the MYPT2 gene, then anti-M₂₁ antibodies should recognise a 21 kDa protein in smooth muscle and a 110 kDa protein in tissues where the full length MYPT2 protein is expressed. The results presented in Fig. 3 are consistent with this scenario. The antibody raised against M₂₁ from chicken gizzard recognised a 22 kDa protein in five rat smooth muscles (small intestine, aorta, stomach, bladder and uterus) whose electrophoretic mobility was slightly slower than that of the M₂₁ subunit from chicken gizzard, but the same antibody detected a 110 kDa protein in rat brain and rat cardiac muscle (Fig. 3). Similar results were obtained in chicken tissues, where the M₂₁ antibody recognised 20 kDa and/or 21 kDa proteins in three smooth muscles (gizzard, aorta and small intestine), but recognised 110 kDa proteins in brain and cardiac muscle that were also expressed (albeit more weakly) in small intestine and aorta (data not shown). Brain and cardiac muscle are the two human tissues where the MYPT2 protein was shown to be expressed most prominently [17]. The myosin P-light chain present in cardiac muscle is not the same gene product as the P-light chain found in skeletal muscle [21]. The expression pattern of MYPT2 therefore suggests that this protein may not only enhance the dephosphorylation of skeletal muscle myosin, but also the dephosphorylation of cardiac myosin and brain myosin.

Although the mRNA encoding MYPT2 is highly expressed in skeletal muscle, Fujioka et al. [17] failed to detect any MYPT2 protein in this tissue by immunoblotting. Our antibody raised against the chicken gizzard M₂₁ subunit also failed to detect an immunoreactive 110 kDa protein in skeletal muscle extracts, although it weakly recognised a 90 kDa protein that might correspond to a proteolytic fragment of MYPT2 (Fig. 3). However, MYPT2 is clearly expressed in skeletal muscle because we isolated it as fragments of a subunit of the major myosin phosphatase in this tissue, and a 55 kDa fragment of MYPT2 was also detected recently by others [22] as a myofibrillar protein from skeletal muscle that binds

to microcystin-Sepharose. The failure to detect MYPT2 by immunoblotting could be explained by its low abundance, since the isolation of PP1M requires over 100 000-fold purification from the myofibrillar fraction of skeletal muscle [8,9], in contrast to the much smaller (1000-fold) purification needed to isolate PP1M from the myofibrils of avian smooth muscle [10]. This low level is consistent with the slow rate of dephosphorylation of the skeletal muscle myosin P-light chain in vivo [23]. Alternatively, the extreme susceptibility of the C-terminus of MYPT2 to proteolysis in skeletal muscle extracts




Fig. 3. Immunoblotting of rat tissues with antibody raised against the M₂₁ subunit from chicken gizzard. Tissue extracts (15 µg extract protein, except for chicken gizzard where 10 µg protein was used) were electrophoresed on 15% SDS-polyacrylamide gels, transferred to nitrocellulose and immunoblotted with affinity-purified anti-M₂₁ antibody using the enhanced chemiluminescence detection system (Amersham). Lane 1, PP1M (0.1 µg) purified from chicken gizzard [10]; lane 2, small intestine; lane 3, aorta; lane 4, brain; lane 5, cardiac muscle; lane 6, stomach; lane 7, bladder; lane 8, uterus; lane 9, skeletal muscle; lane 10, chicken gizzard. The positions of the marker proteins glycogen phosphorylase (97 kDa), bovine serum albumin (66 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa) and soybean trypsin inhibitor (20 kDa) are indicated.

may have prevented detection by our antibody which recognises the C-terminus of the protein.

Acknowledgements: We thank Dr Nick Helps for valuable discussions. This work was supported by the UK Medical Research Council, the Royal Society of London and the Louis Jeantet Foundation (P.C.). We thank the MRC for the award of a Postgraduate Studentship (to D.J.) and the Canadian Natural Sciences and Engineering Research Council for a Postdoctoral Research fellowship (to G.M.).

References

- [1] Hubbard, M.J. and Cohen, P. (1993) *Trends Biochem. Sci.* 18, 172–177.
- [2] Egloff, M.P., Johnson, D.F., Moorhead, G., Cohen, P.T.W., Cohen, P. and Barford, D. (1997) *EMBO J.* 16, 1876–1887.
- [3] Trinkle-Mulcahy, L., Ajuh, P., Prescott, A., Cohen, S., Lamond, A.I. and Cohen, P. (1998) *J. Cell Sci.* (submitted).
- [4] Zhao, S. and Lee, E.Y.C. (1997) *J. Biol. Chem.* 272, 28368–28372.
- [5] Kreivi, J.P., Trinkle-Mulcahy, L., Lyon, C.E., Morrice, N.A., Cohen, P. and Lamond, I.A. (1997) *FEBS Lett.* 420, 57–62.
- [6] Chishom, A.A.K. and Cohen, P. (1988) *Biochim. Biophys. Acta* 968, 392–400.
- [7] Chishom, A.A.K. and Cohen, P. (1988) *Biochim. Biophys. Acta* 971, 163–169.
- [8] Dent, P., MacDougall, L.K., MacKintosh, C., Campbell, D.G. and Cohen, P. (1992) *Eur. J. Biochem.* 210, 1037–1044.
- [9] Moorhead, G., MacKintosh, R.W., Morrice, N., Gallagher, T. and MacKintosh, C. (1994) *FEBS Lett.* 356, 46–50.
- [10] Alessi, D.R., MacDougall, L.K., Sola, M.M., Ikebe, M. and Cohen, P. (1992) *Eur. J. Biochem.* 210, 1023–1035.
- [11] Shimizu, H., Ito, M., Miyahara, M., Ichikawa, K., Okubo, S., Konishi, T., Naka, M., Tanaka, T., Hirano, K., Hartshorne, D.J. and Nakano, T. (1994) *J. Biol. Chem.* 269, 30407–30411.
- [12] Chen, Y.-H., Chen, M.-X., Alessi, D.R., Campbell, D.G., Shanahan, C., Cohen, P. and Cohen, P.T.W. (1994) *FEBS Lett.* 356, 51–56.
- [13] Shirazi, A., Iizuka, K., Fadden, P., Mosse, C., Somlyo, A.P., Somlyo, A.V. and Haystead, T.A.J. (1994) *J. Biol. Chem.* 269, 31598–31606.
- [14] Takahashi, N., Ito, M., Tanaka, J., Nakano, T., Kaibuchi, K., Odai, H. and Takemura, K. (1997) *Genomics* 44, 150–152.
- [15] Johnson, D.F., Moorhead, G., Caudwell, F.B., Cohen, P., Chen, Y.H., Chen, M.X. and Cohen, P.T.W. (1996) *Eur. J. Biochem.* 239, 317–325.
- [16] Johnson, D.F., Cohen, P., Chen, Y.H., Chen, M.X. and Cohen, P.T.W. (1997) *Eur. J. Biochem.* 244, 931–939.
- [17] Fujjoka, M., Takahashi, N., Odai, H., Araki, S., Ichikawa, K., Feng, J., Nakamura, M., Kaibuchi, K., Hartshorne, D.J., Nakano, T. and Ito, M. (1998) *Genomics* 49, 59–68.
- [18] Cuenda, A., Alonso, G., Morrice, N., Jones, M., Meier, R., Cohen, P. and Nebreda, A.R. (1996) *EMBO J.* 15, 4156–4164.
- [19] Sasaki, K., Shima, H., Kitagawa, Y., Irino, S., Sugimura, T. and Nagao, M. (1990) *Jpn. J. Cancer Res.* 81, 1272–1280.
- [20] Berndt, N., Campbell, D.G., Caudwell, F.B., Cohen, P., da Cruz e Silva, E.F., da Cruz e Silva, O.B. and Cohen, P.T.W. (1987) *FEBS Lett.* 223, 340–346.
- [21] Collins, J. (1991) *J. Muscle Res. Cell Motil.* 12, 3–25.
- [22] Damer, C.K., Partridge, J., Pearson, W.R. and Haystead, T.A.J. (1998) *J. Biol. Chem.* 273, 24396–24405.
- [23] Stull, J.T. (1988) in: *Molecular Aspects of Cellular Regulation* (Cohen, P. and Klee, C.B., Eds.), Vol. 5, pp. 91–122, Elsevier Science, Amsterdam.